WO2005082892A3 - Triazole compounds as antibacterial agents and pharmaceutical compositions containing them - Google Patents

Triazole compounds as antibacterial agents and pharmaceutical compositions containing them Download PDF

Info

Publication number
WO2005082892A3
WO2005082892A3 PCT/IB2005/000343 IB2005000343W WO2005082892A3 WO 2005082892 A3 WO2005082892 A3 WO 2005082892A3 IB 2005000343 W IB2005000343 W IB 2005000343W WO 2005082892 A3 WO2005082892 A3 WO 2005082892A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
compositions containing
triazole compounds
antibacterial agents
compounds
Prior art date
Application number
PCT/IB2005/000343
Other languages
French (fr)
Other versions
WO2005082892A2 (en
Inventor
Jagattaran Das
Mohamed Takhi
Selvakumar Natesan
Sanjay Trehan
Javed Iqbal
Sitaram Kumar Magadi
Sreenivas Kandepu
Original Assignee
Reddys Lab Ltd Dr
Jagattaran Das
Mohamed Takhi
Selvakumar Natesan
Sanjay Trehan
Javed Iqbal
Sitaram Kumar Magadi
Sreenivas Kandepu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr, Jagattaran Das, Mohamed Takhi, Selvakumar Natesan, Sanjay Trehan, Javed Iqbal, Sitaram Kumar Magadi, Sreenivas Kandepu filed Critical Reddys Lab Ltd Dr
Publication of WO2005082892A2 publication Critical patent/WO2005082892A2/en
Publication of WO2005082892A3 publication Critical patent/WO2005082892A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to novel triazole compounds of formula (I), where all symbols are as defined in the detailed description; their pharmaceutically acceptable salts their stereosiomers thereof, their prodrugs, their rotamers, their pharmaceutical compositions containing them. The present invention also relates to a process for the preparation of the above said novel compounds.
PCT/IB2005/000343 2004-02-17 2005-02-11 Triazole compounds as antibacterial agents and pharmaceutical compositions containing them WO2005082892A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN120/CHE/2004 2004-02-17
IN120CH2004 2004-02-17

Publications (2)

Publication Number Publication Date
WO2005082892A2 WO2005082892A2 (en) 2005-09-09
WO2005082892A3 true WO2005082892A3 (en) 2006-03-23

Family

ID=34897727

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/000343 WO2005082892A2 (en) 2004-02-17 2005-02-11 Triazole compounds as antibacterial agents and pharmaceutical compositions containing them

Country Status (1)

Country Link
WO (1) WO2005082892A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101195801B1 (en) 2004-06-18 2012-11-05 밀레니엄 파머슈티컬스 인코퍼레이티드 Factor xa inhibitors
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
EP1976837A1 (en) * 2006-01-19 2008-10-08 Laboratorios SALVAT, S.A. Dicarbonylic compounds with antibacterial activity
BRPI0711296A2 (en) 2006-05-05 2011-08-23 Millennium Phamaceutical Inc xa factor inhibitors
DE102006059317A1 (en) 2006-07-04 2008-01-10 Evonik Degussa Gmbh Process for the preparation of β-amino-α-hydroxy-carboxylic acid amides
JP5796872B2 (en) 2009-12-17 2015-10-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Crystalline salt of factor Xa inhibitor
US8742120B2 (en) 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
CA2905993C (en) 2013-03-14 2022-12-06 Tolero Pharmaceuticals, Inc. Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors
WO2014143659A1 (en) 2013-03-15 2014-09-18 Araxes Pharma Llc Irreversible covalent inhibitors of the gtpase k-ras g12c
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
TWI659021B (en) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Inhibitors of kras g12c
JO3556B1 (en) 2014-09-18 2020-07-05 Araxes Pharma Llc Combination therapies for treatment of cancer
US9862701B2 (en) 2014-09-25 2018-01-09 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
KR20180005178A (en) 2015-04-10 2018-01-15 아락세스 파마 엘엘씨 Substituted quinazoline compounds and methods for their use
WO2016168540A1 (en) 2015-04-15 2016-10-20 Araxes Pharma Llc Fused-tricyclic inhibitors of kras and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356353A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
TW201726656A (en) 2015-11-16 2017-08-01 亞瑞克西斯製藥公司 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
JP7327802B2 (en) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー Fused hetero-heterobicyclic compounds and methods of use thereof
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
WO2018218071A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
US11013741B1 (en) 2018-04-05 2021-05-25 Sumitomo Dainippon Pharma Oncology, Inc. AXL kinase inhibitors and use of the same
CN112512597A (en) 2018-07-26 2021-03-16 大日本住友制药肿瘤公司 Methods for treating diseases associated with aberrant ACVR1 expression and ACVR1 inhibitors useful therefor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009328A1 (en) * 1995-09-01 1997-03-13 Pharmacia & Upjohn Company Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings
WO1997030995A1 (en) * 1996-02-24 1997-08-28 Zeneca Limited Antibiotic oxazolidinone derivatives
WO2001040222A1 (en) * 1999-12-03 2001-06-07 Astrazeneca Ab Substituted isoxazolines and their use as antibacterial agents
WO2003008395A1 (en) * 2001-07-20 2003-01-30 Laboratorios S.A.L.V.A.T., S.A. Substituted isoxazoles and the use thereof as antibiotics
WO2003059894A1 (en) * 2002-01-18 2003-07-24 Dr.Reddy's Laboratories Ltd. Novel antibacterial compounds:process for their preparation and pharmaceutical compositions containing them.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009328A1 (en) * 1995-09-01 1997-03-13 Pharmacia & Upjohn Company Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings
WO1997030995A1 (en) * 1996-02-24 1997-08-28 Zeneca Limited Antibiotic oxazolidinone derivatives
WO2001040222A1 (en) * 1999-12-03 2001-06-07 Astrazeneca Ab Substituted isoxazolines and their use as antibacterial agents
WO2003008395A1 (en) * 2001-07-20 2003-01-30 Laboratorios S.A.L.V.A.T., S.A. Substituted isoxazoles and the use thereof as antibiotics
WO2003059894A1 (en) * 2002-01-18 2003-07-24 Dr.Reddy's Laboratories Ltd. Novel antibacterial compounds:process for their preparation and pharmaceutical compositions containing them.

Also Published As

Publication number Publication date
WO2005082892A2 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
WO2005082892A3 (en) Triazole compounds as antibacterial agents and pharmaceutical compositions containing them
CA2499330A1 (en) New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
WO2007138472A3 (en) Triazolopyridazine derivatives
WO2004062601A3 (en) Antibacterial agents
WO2006087543A8 (en) Antibacterial piperidine derivatives
WO2007120647A3 (en) Compositions useful as inhibitors of voltage-gated sodium channels
GEP20115174B (en) Triazolopyrazine derivatives useful as anti-cancer agents
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
TW200716121A (en) Acetylenyl-pyrazolo-pyrimidine derivatives as mGluR2 antagonists
CA2510853A1 (en) Pyrrolopyrimidine derivatives
WO2004062613A3 (en) Hiv integrase inhibitors
TW200616995A (en) Novel compounds
WO2006114520A3 (en) Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof
TW200643013A (en) Pyrazoles
WO2006117211A3 (en) Urea derivatives methods for their manufacture and uses thereof
WO2006077025A3 (en) Morpholines as 5ht2c agonists
WO2004096800A3 (en) Quinuclidine derivatives binding to mucarinic m3 receptors
WO2009082134A3 (en) Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent
WO2007034279A3 (en) C3a antagonists and pharmaceutical compositions thereof
MY150497A (en) New camptothecin analogue compounds, a process for their preparation and pharmaceutical compositions containing them
WO2007017728A3 (en) Novel heterocyclic compounds
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
TW200639156A (en) New compounds
WO2008006795A3 (en) Indole compounds
WO2005040171A8 (en) Pyrazolo and imidazo-pyrimidine derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase